Medarex And PharmAthene Announce New Therapeutic Data For Anthrax Anti-Toxin, Valortim(R)
Oct 29th 2008Drug InformationBio-terrorism
Medarex, Inc. (Nasdaq: MEDX), a leading monoclonal antibody company, and PharmAthene, Inc. (NYSE: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced results from a pilot study showing that the anthrax anti-toxin, Valortim(R) (MDX-1303), enhanced survival as compared to a control group in a therapeutic animal model known as the New Zealand White (NZW) rabbit model.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
